Hui Xu

Dr. Hui Xu

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2023 in The FEBS Journal
Verified
Journal Article
Open access
HKHao Kuang
Hao Kuang
XSXuehua Sun
Xuehua Sun
YLYing Liu
Ying Liu
MTMeng Tang
Meng Tang
YWYan Wei
Yan Wei
FZFuxiang Zhou
Fuxiang Zhou
Ferroptosis, featuring an iron‐dependent peroxidation of lipids, is a novel form of programmed cell death that may hold great potential in cancer therapy. Our study found that palmitic acid (PA) inhibited colon cancer cell viability in vitro and in vivo, in conjunction with an accumulation of reactive oxygen species and lipid peroxidation. The ferroptosis inhibitor Ferrostatin‐1 but not Z‐VAD‐FMK (a pan‐caspase inhibitor), Necrostatin‐1 (a potent necroptosis inhibitor), or CQ (a potent inhibitor of autophagy), rescued the cell death phenotype induced by PA. Subsequently, we verified that PA induces ferroptotic cell death through excess iron as cell death was inhibited by iron chelator deferiprone (DFP), while it was exacerbated by a supplement of ferric ammonium citrate. Mechanistically, PA affects intracellular iron content by inducing endoplasmic reticulum (ER) stress leading to ER calcium release and regulating transferrin (TF) transport through increasing cytosolic calcium levels. Furthermore, we observed that cells with high expression of CD36 were more vulnerable to PA‐induced ferroptosis. Altogether, our findings reveal that PA engages in anti‐cancer properties by activating ER stress/ER calcium release/TF‐dependent ferroptosis, and PA might serve as a compound to activate ferroptosis in colon cancer cells with high CD36 expression.

20 March 2023 in The FEBS Journal
Verified
Journal Article
Closed access
YWYan Wei
Yan Wei
GXGuohui Xiao
Guohui Xiao
HXHui Xu
Hui Xu
XSXuehua Sun
Xuehua Sun
YSYingying Shi
Yingying Shi
FZFuxiang Zhou
Fuxiang Zhou

1 January 2020
Verified
Journal Article
Closed access
LCLulu Chen
Lulu Chen
JPJin Peng
Jin Peng
YWYou Wang
You Wang
HJHuangang Jiang
Huangang Jiang
WWWenbo Wang
Wenbo Wang
ZFZhou Fuxiang
Zhou Fuxiang

29 August 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XZXu Zhu
Xu Zhu
JXJing Xue
Jing Xue
ZLZheng Liu
Zheng Liu
WDWenjie Dai
Wenjie Dai
JXJingsha Xiang
Jingsha Xiang
WCWenhang Chen
Wenhang Chen
Background: The safety of prescribing angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) during acute kidney injury (AKI) remains unclear. We aimed to investigate the associations of ACEI/ARB therapy in AKI with the risk of mortality, acute kidney disease (AKD), and hyperkalemia.Methods: We conducted a retrospective monocentric study, which included patients in Massachusetts between 2008 and 2019 from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Propensity score matching was performed for the endpoint analysis. The association between ACEI/ARB therapy and mortality was assessed using Cox proportional hazards regression models. Logistic regression was used to assess the risk of AKD and hyperkalemia.Results: Among the 19,074 individuals with AKI admitted to the intensive care unit (ICU), 3,244 (17.0%) received ACEI/ARBs, while 15,830 (83.0%) did not. In the propensity score-matched sample of 6,358 individuals, we found a decreased risk of mortality in those who received ACEI/ARBs compared to those who did not (hazard ratio [HR] for ICU mortality: 0.34, 95% confidence interval [CI]: 0.27–0.42); HR for in-hospital mortality: 0.47, 95% CI: 0.39–0.56; HR for 30-day mortality: 0.47, 95% CI: 0.40–0.56; HR for 180-day mortality: 0.53, 95% CI: 0.45–0.62). However, the use of ACEI/ARBs was associated with a higher risk of AKD (risk ratio [RR]: 1.81; 95% CI: 1.55–2.12). There was no significant association between ACEI/ARBs and an increased risk of hyperkalemia (RR: 1.21; 95% CI: 0.96–1.51).Conclusions: ACEI/ARB treatment during an episode of AKI may decrease all-cause mortality, but increases the risk of AKD. Future randomized controlled trials are warranted to validate these findings.

14 June 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
YLYongge Luo
Yongge Luo
LYLEI YANG
LEI YANG
HWHan Wu
Han Wu
HXHui Xu
Hui Xu
JPJin Peng
Jin Peng
ZFZhou Fuxiang
Zhou Fuxiang
The relationship between type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC) has long been extensively recognized, but their crosstalk mechanisms based on gene regulation remain elusive. In our study, for the first time, bulk RNA-seq and single-cell RNA-seq data were used to explore the shared molecular mechanisms between T2DM and CRC. Moreover, Connectivity Map and molecular docking were employed to determine potential drugs targeting the candidate targets. Eight genes (EVPL, TACSTD2, SOX4, ETV4, LY6E, MLXIPL, ENTPD3, UGP2) were identified as characteristic comorbidity genes for T2DM and CRC, with EVPL and ENTPD3 further identified as core comorbidity genes. Our results demonstrated that upregulation of EVPL and downregulation of ENTPD3 were intrinsic molecular features throughout T2DM and CRC and were significantly associated with immune responses, immune processes, and abnormal immune landscapes in both diseases. Single-cell analysis highlighted a cancer-associated fibroblast (CAF) subset that specifically expressed ENTPD3 in CRC, which exhibited high heterogeneity and unique tumor-suppressive features that were completely different from classical cancer-promoting CAFs. Furthermore, ENTPD3+ CAFs could notably predict immunotherapy response in CRC, holding promise to be an immunotherapy biomarker at the single-cell level. Finally, we identified that droperidol may be a novel drug simultaneously targeting EVPL and ENTPD3. In conclusion, previous studies have often focused solely on metabolic alterations common to T2DM and CRC. Our study establishes EVPL and ENTPD3 as characteristic molecules and immune biomarkers of comorbidity in T2DM and CRC patients, and emphasizes the importance of considering immunological mechanisms in the co-development of T2DM and CRC.

4 October 2012 in Journal of Central South University
Verified
Journal Article
Closed access
PDF file
Weiping LiuWeiping Liu
Weiping Liu
HXHui Xu
Hui Xu
XYXi yun Yang
Xi yun Yang
XSXi-Chang Shi
Xi-Chang Shi
YCYa Chen
Ya Chen